JPMorgan Downgrades Infinity Pharmaceutical (INFI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
William Blair Downgrades Infinity Pharmaceutical (INFI) to Market Perform
June 15, 2016 7:51 AM EDTWilliam Blair downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Outperform to Market Perform with a price target of $2.00 (from $20.00).
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $1.36 yesterday.
... MoreMorgan Stanley Downgrades Infinity Pharmaceutical (INFI) to Equalweight
June 15, 2016 7:50 AM EDTMorgan Stanley downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Overweight to Equalweight with a price target of $1.00 (from $11.00).
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $1.36 yesterday.
... MoreFBR Capital Downgrades Infinity Pharmaceutical (INFI) to Market Perform
June 14, 2016 3:43 PM EDTFBR Capital downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Outperform to Market Perform with a price target of $2.00 (from $15.00).
Analyst Christopher James commented, "We are downgrading our rating of Infinity Pharmaceuticals to Market Perform and lowering our price target to $2 from $15 following disappointing data from Infinity's Phase II DYNAMO study with duvelisib in patients with... More
Infinity Pharma (INFI) says to have filing discussions with FDA this summer - Bloomberg
June 14, 2016 8:45 AM EDTInfinity Pharma (NASDAQ: INFI) says to have filing discussions with FDA this summer, according to Bloomberg.
... MoreInfinity Pharma (INFI) Announces Duvelisib Phase 2 Met Primary Endpoint in r/r NHL; Will Undertake Restructuring
June 14, 2016 6:30 AM EDTInfinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that DYNAMO, a registration-focused Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint of overall response rate. In the study, duvelisib demonstrated an overall response rate (ORR) of 46 percent, all of which were partial responses, among 129 patients with iNHL. The majority of reported side effects were reversible and clinically manageable.
"While the DYNAMO study met its primary endpoint, we... More
